HRP20030053A2 - Novel compounds and their use as glycine transport inhibitors - Google Patents
Novel compounds and their use as glycine transport inhibitors Download PDFInfo
- Publication number
- HRP20030053A2 HRP20030053A2 HR20030053A HRP20030053A HRP20030053A2 HR P20030053 A2 HRP20030053 A2 HR P20030053A2 HR 20030053 A HR20030053 A HR 20030053A HR P20030053 A HRP20030053 A HR P20030053A HR P20030053 A2 HRP20030053 A2 HR P20030053A2
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- phenyl
- propyl
- independently represent
- chloro
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 41
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 title description 22
- 239000004471 Glycine Substances 0.000 title description 13
- 239000003112 inhibitor Substances 0.000 title description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 42
- 229910052739 hydrogen Inorganic materials 0.000 claims description 36
- 239000001257 hydrogen Substances 0.000 claims description 36
- 229910052736 halogen Inorganic materials 0.000 claims description 26
- 150000002367 halogens Chemical class 0.000 claims description 26
- 125000003118 aryl group Chemical group 0.000 claims description 21
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 17
- 150000002431 hydrogen Chemical class 0.000 claims description 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 16
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 102000010726 Glycine Plasma Membrane Transport Proteins Human genes 0.000 claims description 13
- 108010063380 Glycine Plasma Membrane Transport Proteins Proteins 0.000 claims description 13
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 229920006395 saturated elastomer Polymers 0.000 claims description 11
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 9
- 201000000980 schizophrenia Diseases 0.000 claims description 9
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 8
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 206010012289 Dementia Diseases 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 208000028017 Psychotic disease Diseases 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 208000030507 AIDS Diseases 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010019196 Head injury Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 208000005314 Multi-Infarct Dementia Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 201000004810 Vascular dementia Diseases 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000004434 sulfur atom Chemical group 0.000 claims description 3
- 125000006621 (C3-C8) cycloalkyl-(C1-C6) alkyl group Chemical group 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 230000008485 antagonism Effects 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 230000037410 cognitive enhancement Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 59
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 229960002449 glycine Drugs 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- -1 phencyclidine Chemical class 0.000 description 9
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 7
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- CDVLPBUKUVKVBA-UEDXYCIISA-N (2s)-2-[3-[5-chloro-1-(4-chlorophenyl)-2,3-dihydroinden-1-yl]propyl-methylamino]propanoic acid Chemical compound C1CC2=CC(Cl)=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=C(Cl)C=C1 CDVLPBUKUVKVBA-UEDXYCIISA-N 0.000 description 3
- RBAQCYGDDPOWCE-UHFFFAOYSA-N 2-[3-[1-(4-chlorophenyl)-5-(4-methylphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C=1C=C2C(CCCN(C)CC(O)=O)(C=3C=CC(Cl)=CC=3)OCC2=CC=1C1=CC=C(C)C=C1 RBAQCYGDDPOWCE-UHFFFAOYSA-N 0.000 description 3
- PFUNWACYBDHFAL-UHFFFAOYSA-N 2-[3-[5-bromo-1-(4-chlorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1CC2=CC(Br)=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(Cl)C=C1 PFUNWACYBDHFAL-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- KEIDEHNAVGKQCB-NVHKAFQKSA-N (2s)-2-[3-(3,3-dimethyl-1-phenyl-2-benzothiophen-1-yl)propyl-methylamino]propanoic acid Chemical compound S1C(C)(C)C2=CC=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=CC=C1 KEIDEHNAVGKQCB-NVHKAFQKSA-N 0.000 description 2
- AQFYBBOVSHVEKK-CPFIQGLUSA-N (2s)-2-[3-[1-(4-chlorophenyl)-3,3-diethyl-2-benzofuran-1-yl]propyl-methylamino]propanoic acid Chemical compound C12=CC=CC=C2C(CC)(CC)OC1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=C(Cl)C=C1 AQFYBBOVSHVEKK-CPFIQGLUSA-N 0.000 description 2
- BLRLFAJWSBAXFC-YXWRBFHGSA-N (2s)-2-[3-[5-chloro-1-(4-chlorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]propanoic acid Chemical compound O1CC2=CC(Cl)=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=C(Cl)C=C1 BLRLFAJWSBAXFC-YXWRBFHGSA-N 0.000 description 2
- BDLPQYZTXBBTQE-YPHUNTSASA-N (2s)-2-[methyl-[3-(3-methyl-1-phenyl-3h-2-benzofuran-1-yl)propyl]amino]propanoic acid Chemical compound O1C(C)C2=CC=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=CC=C1 BDLPQYZTXBBTQE-YPHUNTSASA-N 0.000 description 2
- XKOQVRLECUULHT-UHFFFAOYSA-N 2-[2-[1-(4-chlorophenyl)-3,3-dimethyl-2-benzofuran-1-yl]ethyl-methylamino]acetic acid Chemical compound O1C(C)(C)C2=CC=CC=C2C1(CCN(C)CC(O)=O)C1=CC=C(Cl)C=C1 XKOQVRLECUULHT-UHFFFAOYSA-N 0.000 description 2
- CIWXIAJJCJIWOE-UHFFFAOYSA-N 2-[2-[1-(4-chlorophenyl)-5-(5-chlorothiophen-2-yl)-3h-2-benzofuran-1-yl]ethyl-methylamino]acetic acid Chemical compound C=1C=C2C(CCN(C)CC(O)=O)(C=3C=CC(Cl)=CC=3)OCC2=CC=1C1=CC=C(Cl)S1 CIWXIAJJCJIWOE-UHFFFAOYSA-N 0.000 description 2
- SHIGDERHWRPXFW-UHFFFAOYSA-N 2-[3-[1,5-bis(4-chlorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C=1C=C2C(CCCN(C)CC(O)=O)(C=3C=CC(Cl)=CC=3)OCC2=CC=1C1=CC=C(Cl)C=C1 SHIGDERHWRPXFW-UHFFFAOYSA-N 0.000 description 2
- SPHUZYRFLZYOHP-UHFFFAOYSA-N 2-[3-[1-(4-chlorophenyl)-5-(2,5-dichlorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C=1C=C2C(CCCN(C)CC(O)=O)(C=3C=CC(Cl)=CC=3)OCC2=CC=1C1=CC(Cl)=CC=C1Cl SPHUZYRFLZYOHP-UHFFFAOYSA-N 0.000 description 2
- PIUPRVAVNBKRAQ-UHFFFAOYSA-N 2-[3-[1-(4-chlorophenyl)-5-(2-methylphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C=1C=C2C(CCCN(C)CC(O)=O)(C=3C=CC(Cl)=CC=3)OCC2=CC=1C1=CC=CC=C1C PIUPRVAVNBKRAQ-UHFFFAOYSA-N 0.000 description 2
- JMZRXZUYTKWUCL-UHFFFAOYSA-N 2-[3-[1-(4-chlorophenyl)-5-(3,4-dichlorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C=1C=C2C(CCCN(C)CC(O)=O)(C=3C=CC(Cl)=CC=3)OCC2=CC=1C1=CC=C(Cl)C(Cl)=C1 JMZRXZUYTKWUCL-UHFFFAOYSA-N 0.000 description 2
- OUFAHQPFGFOCCL-UHFFFAOYSA-N 2-[3-[1-(4-chlorophenyl)-5-(3-methylphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C=1C=C2C(CCCN(C)CC(O)=O)(C=3C=CC(Cl)=CC=3)OCC2=CC=1C1=CC=CC(C)=C1 OUFAHQPFGFOCCL-UHFFFAOYSA-N 0.000 description 2
- OEEPPXCUYXQRLI-UHFFFAOYSA-N 2-[3-[1-(4-chlorophenyl)-5-(4-methoxyphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C1=CC(OC)=CC=C1C1=CC=C2C(C=3C=CC(Cl)=CC=3)(CCCN(C)CC(O)=O)OCC2=C1 OEEPPXCUYXQRLI-UHFFFAOYSA-N 0.000 description 2
- TXGJKJXYOREALM-UHFFFAOYSA-N 2-[3-[1-(4-chlorophenyl)-5-[3-(trifluoromethyl)phenyl]-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C=1C=C2C(CCCN(C)CC(O)=O)(C=3C=CC(Cl)=CC=3)OCC2=CC=1C1=CC=CC(C(F)(F)F)=C1 TXGJKJXYOREALM-UHFFFAOYSA-N 0.000 description 2
- JUWVFZAPYCYAKO-UHFFFAOYSA-N 2-[3-[1-(4-chlorophenyl)-5-[4-(trifluoromethyl)phenyl]-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C=1C=C2C(CCCN(C)CC(O)=O)(C=3C=CC(Cl)=CC=3)OCC2=CC=1C1=CC=C(C(F)(F)F)C=C1 JUWVFZAPYCYAKO-UHFFFAOYSA-N 0.000 description 2
- RTWGCBZBZKLFHN-UHFFFAOYSA-N 2-[3-[4-chloro-1-(4-chlorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1CC(C(=CC=C2)Cl)=C2C1(CCCN(C)CC(O)=O)C1=CC=C(Cl)C=C1 RTWGCBZBZKLFHN-UHFFFAOYSA-N 0.000 description 2
- YERIVNORZKQTBA-UHFFFAOYSA-N 2-[3-[5-chloro-1-(4-chlorophenyl)-2,3-dihydroinden-1-yl]propyl-methylamino]acetic acid Chemical compound C1CC2=CC(Cl)=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(Cl)C=C1 YERIVNORZKQTBA-UHFFFAOYSA-N 0.000 description 2
- CYKZSTVLKQCCOE-UHFFFAOYSA-N 2-[3-[5-cyano-1-(4-fluoro-3-methylphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(F)C(C)=C1 CYKZSTVLKQCCOE-UHFFFAOYSA-N 0.000 description 2
- BYEFBPYBYKBWFR-UHFFFAOYSA-N 2-[3-[5-cyano-1-(4-fluorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(F)C=C1 BYEFBPYBYKBWFR-UHFFFAOYSA-N 0.000 description 2
- ZFKXLIIUEFDRBB-UHFFFAOYSA-N 2-[3-[5-cyano-1-(4-methoxyphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C1=CC(OC)=CC=C1C1(CCCN(C)CC(O)=O)C2=CC=C(C#N)C=C2CO1 ZFKXLIIUEFDRBB-UHFFFAOYSA-N 0.000 description 2
- BQAUJJODONZZMO-UHFFFAOYSA-N 2-[3-[6-chloro-1-(4-chlorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1CC2=CC=C(Cl)C=C2C1(CCCN(C)CC(O)=O)C1=CC=C(Cl)C=C1 BQAUJJODONZZMO-UHFFFAOYSA-N 0.000 description 2
- FPZVLWDUJCYRDE-UHFFFAOYSA-N 2-[3-[6-chloro-1-(4-methylphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1CC2=CC=C(Cl)C=C2C1(CCCN(C)CC(O)=O)C1=CC=C(C)C=C1 FPZVLWDUJCYRDE-UHFFFAOYSA-N 0.000 description 2
- GXOOUMOOGHJCHS-UHFFFAOYSA-N 2-[methyl-[3-(3-methyl-1-phenylinden-1-yl)propyl]amino]acetic acid Chemical compound C1=C(C)C2=CC=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=CC=C1 GXOOUMOOGHJCHS-UHFFFAOYSA-N 0.000 description 2
- HYHCUOXXBRKVIT-UHFFFAOYSA-N 2-[methyl-[3-[1-(4-methylphenyl)-3h-2-benzofuran-1-yl]propyl]amino]acetic acid Chemical compound O1CC2=CC=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(C)C=C1 HYHCUOXXBRKVIT-UHFFFAOYSA-N 0.000 description 2
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 102100023145 Sodium- and chloride-dependent glycine transporter 1 Human genes 0.000 description 2
- 101710083171 Sodium- and chloride-dependent glycine transporter 1 Proteins 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 230000002152 alkylating effect Effects 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- OSVAYUPHKDNSKR-UHFFFAOYSA-N ethyl 2-[3-[5-cyano-1-(4-fluorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetate Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)CC(=O)OCC)C1=CC=C(F)C=C1 OSVAYUPHKDNSKR-UHFFFAOYSA-N 0.000 description 2
- NTNZTEQNFHNYBC-UHFFFAOYSA-N ethyl 2-aminoacetate Chemical compound CCOC(=O)CN NTNZTEQNFHNYBC-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 229960001269 glycine hydrochloride Drugs 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- RLMHMDMIOFCETG-UBDBMELISA-N (2s)-2-[3-(3,3-diethyl-1-phenyl-2-benzofuran-1-yl)propyl-methylamino]propanoic acid Chemical compound C12=CC=CC=C2C(CC)(CC)OC1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=CC=C1 RLMHMDMIOFCETG-UBDBMELISA-N 0.000 description 1
- TTXZKKPKXJFPSV-YTJLLHSVSA-N (2s)-2-[3-(5-chloro-1-thiophen-2-yl-3h-2-benzofuran-1-yl)propyl-methylamino]propanoic acid Chemical compound O1CC2=CC(Cl)=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=CS1 TTXZKKPKXJFPSV-YTJLLHSVSA-N 0.000 description 1
- BQJWQOOWJOBXGB-ZDGMYTEDSA-N (2s)-2-[3-[1-(4-fluorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]propanoic acid Chemical compound O1CC2=CC=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=C(F)C=C1 BQJWQOOWJOBXGB-ZDGMYTEDSA-N 0.000 description 1
- OCAHTDRUXVBMOW-MXMOWUBCSA-N (2s)-2-[3-[1-(4-fluorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]propanoic acid;hydrochloride Chemical compound Cl.O1CC2=CC=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=C(F)C=C1 OCAHTDRUXVBMOW-MXMOWUBCSA-N 0.000 description 1
- UAUWLEHSOZBEQW-YXWRBFHGSA-N (2s)-2-[3-[1-(4-fluorophenyl)-5-(trifluoromethyl)-3h-2-benzofuran-1-yl]propyl-methylamino]propanoic acid Chemical compound O1CC2=CC(C(F)(F)F)=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=C(F)C=C1 UAUWLEHSOZBEQW-YXWRBFHGSA-N 0.000 description 1
- SXTQZBWYMOQNCU-VYTWEFSNSA-N (2s)-2-[3-[1-(4-fluorophenyl)-5-(trifluoromethyl)-3h-2-benzofuran-1-yl]propyl-methylamino]propanoic acid;hydrochloride Chemical compound Cl.O1CC2=CC(C(F)(F)F)=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=C(F)C=C1 SXTQZBWYMOQNCU-VYTWEFSNSA-N 0.000 description 1
- JSHPGKFTWNDYTC-JQVYNXHMSA-N (2s)-2-[3-[5-chloro-1-(4-chlorophenyl)-2,3-dihydroinden-1-yl]propyl-methylamino]propanoic acid;hydrochloride Chemical compound Cl.C1CC2=CC(Cl)=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=C(Cl)C=C1 JSHPGKFTWNDYTC-JQVYNXHMSA-N 0.000 description 1
- NNMDLTSDCPVATO-VYTWEFSNSA-N (2s)-2-[3-[5-chloro-1-(4-chlorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]propanoic acid;hydrochloride Chemical compound Cl.O1CC2=CC(Cl)=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=C(Cl)C=C1 NNMDLTSDCPVATO-VYTWEFSNSA-N 0.000 description 1
- QNZUEKRUUYXCNU-GZWBLTSWSA-N (2s)-2-[3-[5-cyano-1-(4-cyanophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]propanoic acid Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=C(C#N)C=C1 QNZUEKRUUYXCNU-GZWBLTSWSA-N 0.000 description 1
- TUKYQPWIBZTOSR-BJQOMGFOSA-N (2s)-2-[methyl-[3-(1-phenyl-3h-2-benzothiophen-1-yl)propyl]amino]propanoic acid Chemical compound S1CC2=CC=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=CC=C1 TUKYQPWIBZTOSR-BJQOMGFOSA-N 0.000 description 1
- KKNQZVJEWPHXIG-LBOXEOMUSA-N (2s)-2-[methyl-[3-(1-phenylinden-1-yl)propyl]amino]propanoic acid Chemical compound C1=CC2=CC=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=CC=C1 KKNQZVJEWPHXIG-LBOXEOMUSA-N 0.000 description 1
- CAYQIZIAYYNFCS-UHFFFAOYSA-N (4-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1 CAYQIZIAYYNFCS-UHFFFAOYSA-N 0.000 description 1
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
- UORHYDOYNNNDHW-UHFFFAOYSA-N 1-(4-fluorophenyl)-1-(3-iodopropyl)-3h-2-benzofuran-5-carbonitrile Chemical compound C1=CC(F)=CC=C1C1(CCCI)C2=CC=C(C#N)C=C2CO1 UORHYDOYNNNDHW-UHFFFAOYSA-N 0.000 description 1
- SCTGAEHVEUYYGU-UHFFFAOYSA-N 2-[2-[5-cyano-1-(4-fluorophenyl)-3h-2-benzofuran-1-yl]ethyl-methylamino]acetic acid Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCN(C)CC(O)=O)C1=CC=C(F)C=C1 SCTGAEHVEUYYGU-UHFFFAOYSA-N 0.000 description 1
- PXPLWZYFONHMMS-UHFFFAOYSA-N 2-[2-[5-cyano-1-(4-fluorophenyl)-3h-2-benzofuran-1-yl]ethyl-methylamino]acetic acid;hydrochloride Chemical compound Cl.O1CC2=CC(C#N)=CC=C2C1(CCN(C)CC(O)=O)C1=CC=C(F)C=C1 PXPLWZYFONHMMS-UHFFFAOYSA-N 0.000 description 1
- HOKCJTQMQWEJBK-UHFFFAOYSA-N 2-[3-(3,3-dimethyl-1-phenyl-2-benzothiophen-1-yl)propyl-methylamino]acetic acid Chemical compound S1C(C)(C)C2=CC=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=CC=C1 HOKCJTQMQWEJBK-UHFFFAOYSA-N 0.000 description 1
- JEAKOGHXLPESQX-UHFFFAOYSA-N 2-[3-(3,3-dimethyl-1-phenyl-2-benzothiophen-1-yl)propyl-methylamino]acetic acid;hydrochloride Chemical compound Cl.S1C(C)(C)C2=CC=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=CC=C1 JEAKOGHXLPESQX-UHFFFAOYSA-N 0.000 description 1
- MMEFKIFIMMDSTF-UHFFFAOYSA-N 2-[3-(5-chloro-1-thiophen-2-yl-3h-2-benzofuran-1-yl)propyl-methylamino]acetic acid Chemical compound O1CC2=CC(Cl)=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=CS1 MMEFKIFIMMDSTF-UHFFFAOYSA-N 0.000 description 1
- RQHGELJFTUQRGZ-UHFFFAOYSA-N 2-[3-(5-chloro-1-thiophen-2-yl-3h-2-benzofuran-1-yl)propyl-methylamino]butanoic acid Chemical compound O1CC2=CC(Cl)=CC=C2C1(CCCN(C)C(CC)C(O)=O)C1=CC=CS1 RQHGELJFTUQRGZ-UHFFFAOYSA-N 0.000 description 1
- SQWYCLPSDYACTO-UHFFFAOYSA-N 2-[3-[1-(3-chlorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1CC2=CC=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=CC(Cl)=C1 SQWYCLPSDYACTO-UHFFFAOYSA-N 0.000 description 1
- IIRRRHJJKOOZJJ-UHFFFAOYSA-N 2-[3-[1-(3-chlorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid;hydrochloride Chemical compound Cl.O1CC2=CC=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=CC(Cl)=C1 IIRRRHJJKOOZJJ-UHFFFAOYSA-N 0.000 description 1
- KGPQQENJOWEIII-UHFFFAOYSA-N 2-[3-[1-(4-chlorophenyl)-3,3-dimethyl-2h-inden-1-yl]propyl-methylamino]acetic acid Chemical compound C1C(C)(C)C2=CC=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(Cl)C=C1 KGPQQENJOWEIII-UHFFFAOYSA-N 0.000 description 1
- KAPQYVCDDXBUIY-UHFFFAOYSA-N 2-[3-[1-(4-chlorophenyl)-5-[2-(trifluoromethyl)phenyl]-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C=1C=C2C(CCCN(C)CC(O)=O)(C=3C=CC(Cl)=CC=3)OCC2=CC=1C1=CC=CC=C1C(F)(F)F KAPQYVCDDXBUIY-UHFFFAOYSA-N 0.000 description 1
- LTSWUMKWZXTGOB-UHFFFAOYSA-N 2-[3-[1-(4-chlorophenyl)-5-fluoro-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1CC2=CC(F)=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(Cl)C=C1 LTSWUMKWZXTGOB-UHFFFAOYSA-N 0.000 description 1
- ZLOHYHCNWKILRP-UHFFFAOYSA-N 2-[3-[1-(4-fluorophenyl)-3,3-dimethyl-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1C(C)(C)C2=CC=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(F)C=C1 ZLOHYHCNWKILRP-UHFFFAOYSA-N 0.000 description 1
- BKZQAANJGUQRNB-UHFFFAOYSA-N 2-[3-[1-(4-fluorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1CC2=CC=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(F)C=C1 BKZQAANJGUQRNB-UHFFFAOYSA-N 0.000 description 1
- YBKWCNOLXLQXGL-UHFFFAOYSA-N 2-[3-[1-(4-fluorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid;hydrochloride Chemical compound Cl.O1CC2=CC=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(F)C=C1 YBKWCNOLXLQXGL-UHFFFAOYSA-N 0.000 description 1
- WKFMECNVGHSJRN-UHFFFAOYSA-N 2-[3-[1-(4-fluorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]butanoic acid Chemical compound O1CC2=CC=CC=C2C1(CCCN(C)C(CC)C(O)=O)C1=CC=C(F)C=C1 WKFMECNVGHSJRN-UHFFFAOYSA-N 0.000 description 1
- HPGIDFCZZZSUNU-UHFFFAOYSA-N 2-[3-[1-(4-fluorophenyl)-5-(trifluoromethyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1CC2=CC(C(F)(F)F)=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(F)C=C1 HPGIDFCZZZSUNU-UHFFFAOYSA-N 0.000 description 1
- VYPHKMMGJHXGLO-UHFFFAOYSA-N 2-[3-[1-(4-fluorophenyl)-5-(trifluoromethyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid;hydrochloride Chemical compound Cl.O1CC2=CC(C(F)(F)F)=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(F)C=C1 VYPHKMMGJHXGLO-UHFFFAOYSA-N 0.000 description 1
- ZQQZFRRMHNULQI-UHFFFAOYSA-N 2-[3-[1-(4-fluorophenyl)-5-[4-(trifluoromethyl)phenyl]-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C=1C=C2C(CCCN(C)CC(O)=O)(C=3C=CC(F)=CC=3)OCC2=CC=1C1=CC=C(C(F)(F)F)C=C1 ZQQZFRRMHNULQI-UHFFFAOYSA-N 0.000 description 1
- BGASQIGFXFNAQQ-UHFFFAOYSA-N 2-[3-[4-chloro-1-(4-chlorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid;hydrochloride Chemical compound Cl.O1CC(C(=CC=C2)Cl)=C2C1(CCCN(C)CC(O)=O)C1=CC=C(Cl)C=C1 BGASQIGFXFNAQQ-UHFFFAOYSA-N 0.000 description 1
- KDETUNZZDAVRHR-UHFFFAOYSA-N 2-[3-[4-chloro-1-(4-fluoro-3-methylphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1CC(C(=CC=C2)Cl)=C2C1(CCCN(C)CC(O)=O)C1=CC=C(F)C(C)=C1 KDETUNZZDAVRHR-UHFFFAOYSA-N 0.000 description 1
- JNQZCKBPHCADOP-UHFFFAOYSA-N 2-[3-[4-chloro-1-(4-fluoro-3-methylphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid;hydrochloride Chemical compound Cl.O1CC(C(=CC=C2)Cl)=C2C1(CCCN(C)CC(O)=O)C1=CC=C(F)C(C)=C1 JNQZCKBPHCADOP-UHFFFAOYSA-N 0.000 description 1
- AZNVOIZXPGYOSB-UHFFFAOYSA-N 2-[3-[5-chloro-1-(4-chlorophenyl)-2,3-dihydroinden-1-yl]propyl-methylamino]acetic acid;hydrochloride Chemical compound Cl.C1CC2=CC(Cl)=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(Cl)C=C1 AZNVOIZXPGYOSB-UHFFFAOYSA-N 0.000 description 1
- WKUPMDJWESAHCK-UHFFFAOYSA-N 2-[3-[5-cyano-1-(4-fluoro-3-methylphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid;hydrochloride Chemical compound Cl.O1CC2=CC(C#N)=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(F)C(C)=C1 WKUPMDJWESAHCK-UHFFFAOYSA-N 0.000 description 1
- LKDQVWXBEMADHF-UHFFFAOYSA-N 2-[3-[5-cyano-1-(4-fluorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid;hydrochloride Chemical compound Cl.O1CC2=CC(C#N)=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(F)C=C1 LKDQVWXBEMADHF-UHFFFAOYSA-N 0.000 description 1
- UMOOSINNKYLLDU-UHFFFAOYSA-N 2-[3-[5-cyano-1-(4-fluorophenyl)-3h-2-benzofuran-1-yl]propylamino]acetic acid Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCNCC(=O)O)C1=CC=C(F)C=C1 UMOOSINNKYLLDU-UHFFFAOYSA-N 0.000 description 1
- VWFCLAZEBNWWKY-UHFFFAOYSA-N 2-[3-[5-cyano-1-(4-methoxyphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1C1(CCCN(C)CC(O)=O)C2=CC=C(C#N)C=C2CO1 VWFCLAZEBNWWKY-UHFFFAOYSA-N 0.000 description 1
- WINGQRZUAIJHKN-UHFFFAOYSA-N 2-[3-[5-fluoro-1-(4-methoxyphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1C1(CCCN(C)CC(O)=O)C2=CC=C(F)C=C2CO1 WINGQRZUAIJHKN-UHFFFAOYSA-N 0.000 description 1
- GIUHFAPURGBVFT-UHFFFAOYSA-N 2-[3-[6-chloro-1-(4-chlorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid;hydrochloride Chemical compound Cl.O1CC2=CC=C(Cl)C=C2C1(CCCN(C)CC(O)=O)C1=CC=C(Cl)C=C1 GIUHFAPURGBVFT-UHFFFAOYSA-N 0.000 description 1
- JVQZDCZIFSRDQU-UHFFFAOYSA-N 2-[3-[6-chloro-1-(4-fluoro-3-methylphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1CC2=CC=C(Cl)C=C2C1(CCCN(C)CC(O)=O)C1=CC=C(F)C(C)=C1 JVQZDCZIFSRDQU-UHFFFAOYSA-N 0.000 description 1
- FQMHYNZGTKQLBE-UHFFFAOYSA-N 2-[3-[6-chloro-1-(4-methoxyphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C1=CC(OC)=CC=C1C1(CCCN(C)CC(O)=O)C2=CC(Cl)=CC=C2CO1 FQMHYNZGTKQLBE-UHFFFAOYSA-N 0.000 description 1
- ODHVKYXAEWWGCM-UHFFFAOYSA-N 2-[3-[6-chloro-1-(4-methoxyphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1C1(CCCN(C)CC(O)=O)C2=CC(Cl)=CC=C2CO1 ODHVKYXAEWWGCM-UHFFFAOYSA-N 0.000 description 1
- AXADURWEISCUSH-UHFFFAOYSA-N 2-[3-[6-chloro-1-(4-methylphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid;hydrochloride Chemical compound Cl.O1CC2=CC=C(Cl)C=C2C1(CCCN(C)CC(O)=O)C1=CC=C(C)C=C1 AXADURWEISCUSH-UHFFFAOYSA-N 0.000 description 1
- CEETWSDATDRVAC-UHFFFAOYSA-N 2-[methyl-[3-(3-methyl-1-phenyl-3h-2-benzofuran-1-yl)propyl]amino]butanoic acid Chemical compound O1C(C)C2=CC=CC=C2C1(CCCN(C)C(CC)C(O)=O)C1=CC=CC=C1 CEETWSDATDRVAC-UHFFFAOYSA-N 0.000 description 1
- FWMFQNAGGJQHLP-UHFFFAOYSA-N 2-[methyl-[3-[1-[3-(trifluoromethyl)phenyl]-3h-2-benzofuran-1-yl]propyl]amino]acetic acid Chemical compound O1CC2=CC=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=CC(C(F)(F)F)=C1 FWMFQNAGGJQHLP-UHFFFAOYSA-N 0.000 description 1
- UXYJEJXEISGCGB-UHFFFAOYSA-N 2-[methyl-[3-[1-[3-(trifluoromethyl)phenyl]-3h-2-benzofuran-1-yl]propyl]amino]acetic acid;hydrochloride Chemical compound Cl.O1CC2=CC=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=CC(C(F)(F)F)=C1 UXYJEJXEISGCGB-UHFFFAOYSA-N 0.000 description 1
- WRMMTIZXXADKOG-UHFFFAOYSA-N 2-[methyl-[3-[1-[3-(trifluoromethyl)phenyl]-3h-2-benzofuran-1-yl]propyl]amino]butanoic acid Chemical compound O1CC2=CC=CC=C2C1(CCCN(C)C(CC)C(O)=O)C1=CC=CC(C(F)(F)F)=C1 WRMMTIZXXADKOG-UHFFFAOYSA-N 0.000 description 1
- AZLJECUPHBHYQD-UHFFFAOYSA-N 2-[methyl-[3-[1-[3-(trifluoromethyl)phenyl]-3h-2-benzofuran-1-yl]propyl]amino]butanoic acid;hydrochloride Chemical compound Cl.O1CC2=CC=CC=C2C1(CCCN(C)C(CC)C(O)=O)C1=CC=CC(C(F)(F)F)=C1 AZLJECUPHBHYQD-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- FDXBTCYDTGBJLN-UHFFFAOYSA-N Cl.CC1=CC=C(C=C1)C1(OCC2=CC=CC=C12)CCCN(CC(=O)O)C Chemical compound Cl.CC1=CC=C(C=C1)C1(OCC2=CC=CC=C12)CCCN(CC(=O)O)C FDXBTCYDTGBJLN-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000011714 Glycine Receptors Human genes 0.000 description 1
- 108010076533 Glycine Receptors Proteins 0.000 description 1
- 102000006541 Ionotropic Glutamate Receptors Human genes 0.000 description 1
- 108010008812 Ionotropic Glutamate Receptors Proteins 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 1
- 238000003109 Karl Fischer titration Methods 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 208000002033 Myoclonus Diseases 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241000220304 Prunus dulcis Species 0.000 description 1
- 102100028886 Sodium- and chloride-dependent glycine transporter 2 Human genes 0.000 description 1
- 101710083167 Sodium- and chloride-dependent glycine transporter 2 Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Natural products O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 150000001543 aryl boronic acids Chemical class 0.000 description 1
- 150000001499 aryl bromides Chemical class 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 150000005347 biaryls Chemical class 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- BTKSUULMJNNXHG-UHFFFAOYSA-N ethyl 2-(methylamino)acetate Chemical compound CCOC(=O)CNC BTKSUULMJNNXHG-UHFFFAOYSA-N 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000002332 glycine derivatives Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- WVKIFIROCHIWAY-UHFFFAOYSA-N hydron;2-(methylamino)acetic acid;chloride Chemical class Cl.CNCC(O)=O WVKIFIROCHIWAY-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000001057 ionotropic effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 1
- 229950006874 kainic acid Drugs 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 102000006239 metabotropic receptors Human genes 0.000 description 1
- 108020004083 metabotropic receptors Proteins 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- ULWOJODHECIZAU-UHFFFAOYSA-N n,n-diethylpropan-2-amine Chemical compound CCN(CC)C(C)C ULWOJODHECIZAU-UHFFFAOYSA-N 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000003568 synaptosome Anatomy 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/14—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of carbon skeletons containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/72—Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Ovaj izum predstavlja nove spojeve opće formule I i njihovu uporabu kao inhibitora prijenosa glicina.
Prethodno stanje struke
Glutaminska kiselina je najvažnija poticajna amino kiselina u centralnom živčanom sustavu (CNS) sisavaca, a djeluje preko dviju klasa receptora, ionotropskih odnosno metabotropskih receptora. Ionotropski receptori glutamata dijele se na tri podtipa na temelju afiniteta agonista tih receptora, to jest na receptore N-metil-D-aspartata (NMDA), (R,S)-2-amino-3-(3-hidroksi-5-metilizoksazol-4-il)propanojske kiseline (AMPA) i kainične kiseline (ili kainata).
NMDA receptor sadrži vezne položaje za modulatorne spojeve poput glicina i poliamina. Vezivanje glicina na njegov receptor pospješuje aktiviranje NMDA receptora. To aktiviranje NMDA receptora moglo bi biti potencijalni cilj za liječenje shizofrenije i drugih bolesti vezanih na disfunkciju NMDA receptora. Aktivacija se može postići pomoću inhibitora prijenosnika glicina.
Molekularno kloniranje otkrilo je postojanje dvaju tipova receptora glicina, GlyT-1 i GlyT-2, pri čemu se GlyT-1 još dalje može podijeliti na GlyT-1a, GlyT-1b i GlyT-1c. NMDA receptor blokira se spojevima poput fenciklidina, što izaziva psihotično stanje slično shizofreniji. Isto tako, NMDA antagonisti, poput ketamina, izazivaju negativne i kognitivne simptome slične shizofreniji. To ukazuje na to da disfunkcija receptora NMDA igra ulogu u patofiziologiji shizofrenije. NMDA receptor povezuje se s nizom bolesti, kao što su bol (Yaksh Pain 1989., 37, 111-123), spastičnost, mioklonus i epilepsija (Truong i sur. Movement Disporders 1988., 3, 77-87), učenje i pamćenje (Rison i sur. Neurosci. Biobehav. Rev. 1995., 19, 533-552).
Tako se za antagoniste ili inhibitore prijenosnika glicina vjeruje da su veoma djelotvorni kod liječenja shizofrenije, uključujući i pozitivne i negativne simptome shizofrenije, druge psihoze, demenciju, te poboljšanje shvaćanja u uvjetima u kojima su kognitivni procesi smanjeni, tj. kod Alzheimerove bolesti, multi-infarktne demencije, demencije uzrokovane AIDS-om, Huntingtonove bolesti, Parkinsonove bolesti, amiotropske lateralne skleroze ili bolesti u kojima je mozak oštećen zbog unutrašnjih ili vanjskih utjecaja, poput traume glave ili moždanog udara.
Objavljeni su klinički pokusi s glicinom (Javitt i sur. Am. J. Psychiatry 1994., 151, 1234-1236), (Leiderman i sur. Biol. Psychiatry 1996., 39, 213-215). Opisano je da je liječenje glicinom u visokim dozama poboljšalo simptome shizofrenije. Javlja se potreba za učinkovitijim spojevima kao ligandima prijenosnika glicina za liječenje bolesti povezanih s NMDA.
Spojevi prema ovom izumu snažni su ligandi prijenosnika glicina.
Kratki opis izuma
Ovaj izum predstavlja novi spoj formule I:
[image]
u kojoj
R1 predstavlja vodik, C1-6-alkil, cikloalkil ili cikloalkilalkil;
R2 i R3 neovisno predstavljaju vodik, halogen, C1-6-alkil, C3-8-alkil ili C3-8-cikloalkil-C1-6-alkil ili R2 i R3 zajedno tvore C3-8-cikloalkil;
R4, R5, R6 i R7 neovisno predstavljaju vodik, halogen, CF3, NO2, CN, C1-6-alkil, C2-6-alkenil, C2-6-alkinil, C3-8-cikloalkil, C1-6-alkoksi, C1-6-alkitio, OH, SH, NR14R15, gdje R14 i R15 neovisno predstavljaju vodik ili C1-6-alkil; -COR16, gdje R16 predstavlja OH, C1-6-alkil, C1-6-alkoksi, NR17R18, gdje R17 i R18 neovisno predstavljaju vodik ili C1-6-alkil; aril ili heteroaril, gdje su aril i heteroaril jednom ili više puta zamijenjeni halogenom, CF3, OCF3, CN, NO2, C1-6-alkilom, C2-6-alkenilom, C2-6-alkinilom, C3-8-cikloalkilom, C1-6-alkoksi, C1-6-tioalkilom, OH, SH ili NR24R25, gdje R24 i R25 neovisno predstavljaju vodik ili C1-6-alkil;
ili R4 i R5, ili R5 i R6, ili R6 i R7 zajedno tvore kondenziran, aromatski, zasićen ili djelomično zasićen prsten koji opcionalno sadrži jedan ili više heteroatoma poput O, N ili S;
R8, R9, R10, R11 i R12 neovisno predstavljaju vodik, halogen, CF3, OCF3, CN, NO2, C1-6-alkil, C2-6-alkenil, C2-6-alkinil, C3-8-cikloalkil, C1-6-alkoksi, C1-6-alkitio, OH, SH, NR19R20, gdje R19 i R20 neovisno predstavljaju vodik ili C1-6-alkil; ili R8, R9, R10, R11 i R12 neovisno predstavljaju –COR21, gdje R21 predstavlja OH, C1-6-alkoksi, NR22R23, gdje R22 i R23 neovisno predstavljaju vodik ili C1-6-alkil; ili R8, R9, R10, R11 i R12 neovisno predstavljaju aril ili heteroaril, pri čemu su aril i heteroaril opcionalno jednom ili više puta supstituirani halogenom, CF3, OCF3, CN, NO2, C1-6-alkilom, C2-6-alkenilom, C2-6-alkinilom, C3-8-cikloalkilom, C1-6-alkoksi, C1-6-alkitijem, OH, SH, COR26, gdje R26 predstavlja OH, C1-6-alkoksi ili C1-6-alkil; ili NR30R31, gdje R30 i R31 neovisno predstavljaju vodik ili C1-6-alkil;
R8 i R9, ili R9 i R10, ili R10 i R11, ili R11 i R12 zajedno tvore kondenziran, aromatski, zasićen ili djelomično zasićen prsten koji opcionalno sadrži jedan ili više heteroatoma poput O, N ili S;
Y je O, C, CH2 ili CH, a kad Y znači CH točkasta crta je veza;
n je 2, 3, 4, 5 ili 6;
Q predstavlja C, P-OR29 ili S=O, gdje R29 predstavlja vodik ili C1-6-alkil;
X je OR13 ili NR27R28, gdje R13, R27 i R28 neovisno predstavljaju vodik, C1-6-alkil, aril ili aril-C1-6-alkil, gdje aril može biti supstituiran halogenom, CF3, OCF3, CN, NO2 ili C1-6-alkilom; opcionalno R27 i R28 zajedno tvore prsten koji može sadržavati još i atome dušika, kisika ili sumpora, a prsten može biti djelomično zasićen;
R29 i R30 predstavljaju vodik, C1-6-alkil, cikloalkil ili cikloalkilalkil
ili njihove farmaceutski prihvatljive kiselinske soli.
Ti su spojevi korisni kao inhibitori prijenosnika glicina i korisni u liječenju bolesti odgovornih za inhibiciju prijenosnika glicina.
Detaljni opis izuma
U preferiranoj verziji ovog izuma Q je C;
Druge preferirane verzije su one u kojima je n 2 ili 3;
Daljnja preferirana verzija je ona u kojoj R1 znači CH3;
Još jedna preferirana verzija je ona u kojoj X znači OH ili C1-6-akoksi; još više je preferirana ona u kojoj X znači OH, OCH3 ili OC2H5.
Druge preferirane verzije su one u kojima R7 predstavlja vodik, a R4, R5 ili R6 predstavljaju vodik, CN, halogen, C1-6-alkil, CF3 ili fenil opcionalno jednom ili više puta supstituiran halogenom, C1-6-alkilom, C1-6-alkoksi, CF3, ili R4, R5 i R6 predstavljaju heteroaril opcionalno jednom ili više puta supstituiran halogenom ili gdje R4 i R5 ili R5 i R6 zajedno tvore kondenziran aril.
Još jedna preferirana verzija ovog izuma je ona u kojoj R8, R9, R10, R11 ili R12 neovisno predstavljaju vodik, halogen, C1-6-alkil, C1-6-alkoksi, ili R8 i R9 ili R9 ili R10 zajedno tvore kondenziran aril.
U još više preferiranoj verziji jedan ili dva od R8, R9, R10, R11 ili R12 predstavljaju halogen, C1-6-alkil, CF3 ili C1-6-alkoksi.
U još više preferiranoj verziji ovog izuma R4, R6, R7, R8, R9 i R12 su svi vodik, a R5 predstavlja halogen, CF3, CN, C1-6-alkil, C1-6-alkoksi ili –COR16, gdje R16 predstavlja C1-6-alkil; a R10 i R11 predstavljaju vodik, halogen, CF3 ili CN, pod uvjetom da bar jedan od R10 i R11 ne bude vodik;
R29 i R30 neovisno predstavljaju vodik ili C1-6-alkil ili R2 i R3 zajedno tvore C3-8-cikloalkil.
Još jedna preferirana verzija ovog izuma je ona u kojoj su spojevi sljedeći:
N-{3-[5-Cijano-1-(4-fluorofenil)-1,3-dihidroizobenzofuran-1-il]propil} glicin etil ester,
N-{3-[5-Cijano-1-(4-fluorofenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin etil ester,
N-{3-[5-Cijano-1-(4-fluorofenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}glicin,
N-{3-[5-Cijano-1-(4-fluorofenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin,
N-{3-[1-(3-klorofenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin,
N-{3-[1-(3-trifluorometilfenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin,
N-{3-[1-(3-trifluorometilfenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metil(1-etil)glicin,
N-{3-[1-(4-metilfenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin,
N-{3-[1-(4-fluorofenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin,
N-{3-[1-(4-fluorofenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilalanin,
N-{3-[1-(4-fluorofenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metil(1-etil)glicin,
N-{3-[4-kloro-1-(3-metil-4-fluorofenil)-1,3-dihidroizobenzofuran-1il]-1-propil}-N-metilglicin,
N-{3-[4-kloro-1-(4-klorofenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin,
N-{3-[5-kloro-1-(4-klorofenil)-1,3-dihidroizobenzofuran-1il]-1-propil}-N-metilalanin,
N-{3-[6-kloro-1-(3-metil-4-fluorofenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin,
N-{3-[6-kloro-1-(4-klorofenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin,
N-{3-[6-kloro-1-(4-metilfenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin,
N-{3-[6-kloro-1-(4-metoksifenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin,
N-{3-[5-fluoro-1-(4-klorofenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin,
N-{3-[5-fluoro-1-(4-metoksifenil)-1,3-dihidroizobenzofuran-1-il]-1-}propil-N-metilglicin,
N-{3-[5-trifluorometil-1-(4-fluorofenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin,
N-{3-[5-trifluroometil-1-(4-fluorofenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilalanin,
N-{3-[5-cijano-1-(3-metil-4-fluorofenil)-1,3-dihidroizobenzofuran-1-il]-propil}-N-metilglicin,
N-{3-[5-cijano-1-(4-cijanofenil)-1,3-dihidroizobenzofuran-1-il]-propil}-N-metilalanin,
N-{3-[5-cijano-1-(4-metoksifenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin,
N-{3-[5-cijano-1-(4-fluorofenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin,
N-{2-[5-cijano-1-(4-fluorofenil)-1,3-dihidroizobenzofuran-1-il]etil}-N-metilglicin,
N-{3-[5-Kloro-1-(4-kloro-fenil)-indan-1-il]-propil}-N-metilglicin,
N-{3-[5-Kloro-1-(4-kloro-fenil)-indan-1-il]-propil}-N-metilalanin,
N-{3-[3-ciklo-1-(4-metilfenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin,
N-[3-(3,3-Dimetil-1-fenil-1,3-dihidro-benzo[c]tiofen-1-il)propil]-N-metilglicin,
N-[3-(3,3-Dimetil-1-fenil-1,3-dihidro-benzo[c]tiofen-1-il)-propil]-N-metilalanin,
N-{3-[1-(4-Fluoro-fenil)-3,3-dimetil-1,3-dihidro-izobenzofuran-1-il]-propil}-N-metilglicin,
N-{3-[5-Bromo-1-(4-klorofenil)-1,3-dihidroizobenzofuran-1-il]-propil}-N-metilglicin,
N-{2-[1-(4-Kloro-fenil)-3,3-dimetil-1,3-dihidro-izobenzofuran-1-il]-etil}-N-metilglicin,
N-[3-(3-metil-1-fenil-1H-inden-1-il)-propil]-N-metilglicin,
N-[3-(5-Kloro-1-tiofen-2-il-1,3-dihidro-izobenzofuran-1-il)-propil]-N-metilglicin,
N-[3-(5-Kloro-1-tiofen-1-il-1,3-dihidro-izobenzofuran-1-il)-propil]-N-metil(1-etil)-glicin,
N-[3-(3-metil-1-fenil-1,3-dihidro-izobenzofuran-1-il)-propil]-N-metilalanin,
N-[3-(3-metil-1-fenil-1,3-dihidro-izobenzofuran-1-il)-propil]-N-metil(1-etil)-glicin,
N-[3-(3,3-Dimetil-1-fenil-1,3-dihiro-izobenzofuran-1-il)-etil]-N-metilalanin,
N-[3-(3,3-Dimetil-1-(4-fluoro-fenil)-1,3-dihidro-izobenzofuran-1-il)-etil]-N-metilalanin,
N-[3-(3,3,-Dimetil-1-fenil-1,3-dihiro-izobenzofuran-1-il)-etil]-N-metil-(1-etil) glicin,
N-[3-(3,3-Dimetil-1-(4-fluoro-fenil)-1,3-dihidro-izobenzofuran-1-il)-etil]-N-metil-(1-etil)glicin,
N-[3-(3,3-Dietil-1-fenil-1,3-dihidro-izobenzofuran-1-il)-propil]-N-metilalanin,
N-[3-(3,3-Dietil-1-(4-kloro-fenil)-1,3-dihidro-izobenzofuran-1-il)-propil]-N-metilalanin,
N-[3-(3,3-Dietil-1-(4-kloro-fenil(-1,3-dihidro-izobenzofuran-1-il)-propil]-N-metilglicin,
N-[3-(1-fenil-1,3-dihidro-benzo[c]tiofen-1-il)-propil]-N-metilalanin,
N-{3-[1-(4-Kloro-fenil)-3,3-dimetil-indan-1-il]-propil}-N-metilglicin,
N-{3-[1-(4-Kloro-fenil)-3,3-dietil-1,3-dihidro-izobenzofuran-1-il]-propil}-N-metil-alanin,
N-[2-(3-metil-1-fenil-indan-1il)-etil]-amino}-N-metil alanin,
N-[3-(1-fenil-(1H)-inden-1-il)-propil]-N-metil-alanin,
N-{3-[1-(4-Fluoro-fenil)-5-(4-trifluorometil-fenil)-1,3-dihidro-izobenzofuran-1-il]-propil}-N-metil-glicin,
N-{3-[5-Kloro-1-(4-kloro-fenil)-indan-1il]-propil}-N-metil-glicin,
N-{3-[5-Kloro-1-(4-kloro-fenil)-indan-1il]-propil}-N-metil-alanin,
N-{3-[1-(4-kloro-fenil)-5-(4-trifluorometil-fenil)-1,3-dihidro-izobenzofuran-1-il]-etil}-N-metil-glicin,
N-{3-[1-(4-Kloro-fenil)-5-(4-metil-fenil)-1,3-dihidro-izobenzofuran-1-il]-etil}-N-metil-glicin,
N-{3-[1-(4-Kloro-fenil)-5-(4-metoksi-fenil)-1,3-dihidro-izobenzofuran-1-il]-etil}-N-metil-glicin,
N-{3-[1-(4-Kloro-fenil)-5-(2-tiofenil)-1,3-dihidro-izobenzofuran-1-il]-etil}-N-metil-glicin,
N-{3-[1-(4-Kloro-fenil)-5-(4-metil-fenil)-1,3-dihidro-izobenzofuran-1-il]-propil}-N-metil-glicin,
N-{3-[1-(4-Kloro-fenil)-5-(4-metoksi-fenil)-1,3-dihidro-izobenzofuran-1il]-propil}-N-metil-glicin,
N-{3-[1-(4-kloro-fenil)-5-(4-trifluorometil-fenil)-1,3-dihidro-izobenzofuran-1-il]-propil}-N-metil-glicin,
N-{3-[1-(4-Kloro-fenil)-5-(4-kloro-fenil)-1,3-dihidro-izobenzofuran-1-il]-etil}-N-metil-glicin,
N-{2-[1-(4-Kloro-fenil)-5-(5-kloro-tiofen-2-il)-1,3-dihidro-izobenzofuran-1-il]-etil}-N-metil-glicin,
N-{3-[1-(4-Kloro-fenil)-5-(3-metil-fenil)-1,3-dihidro-izobenzofuran-1-il]-etil}-N-metil-glicin,
N-{3-[1-(4-Kloro-fenil)-5-(2-metil-fenil)-1,3-dihidro-izobenzofuran-1-il]-etil}-N-metil-glicin,
N-{3-[1-(4-Kloro-fenil)-5-(2,5-dikloro-fenil)-1,3-dihidro-izobenzofuran-1-il]-etil}-N-metil-glicin,
N-{3-[1-(4-kloro-fenil)-5-(3-trifluorometil-fenil)-1,3.dihidro-izobenzofuran-1-il]-etil}-N-metil-glicin,
N-{3-[1-(4-kloro-fenil)-5-(3-trifluorometil-fenil)-1,3-dihidro-izobenzofuran-1il]-propil}-N-metil-glicin,
N-{3-[1-(4-Kloro-fenil)-5-(3,4-dikloro-fenil)-1,3-dihidro-izobenzofuran-1-il]-etil}-N-metil-glicin,
N-{3-[1-(4-Kloro-fenil)-5-(4-kloro-fenil)-1,3-dihidro-izobenzofuran-1-il]-propil}-N-metil-glicin,
N-{3-[1-(4-Kloro-fenil)-5-(3-metil-fenil)-1,3-dihidro-izobenzofuran-1-il]-propil}-N-metil-glicin,
N-{3-[1-(4-Kloro-fenil)-5-(2-metil-fenil)-1,3-dihidro-izobenzofuran-1-il]-propil}-N-metil-glicin,
N-{3-[1-(4-Kloro-fenil)-5-(2,5-dikloro-fenil)-1,3-dihidro-izobenzofuran-1-il]-propil}-N-metil-glicin,
N-{3-[1-(4-Kloro-fenil)-5-(3,4-dikloro-fenil)-1,3-dihidro-izobenzofuran-1-il]-propil}-N-metil-glicin,
N-{3-[1-(4-kloro-fenil)-5-(2-trifluorometil-fenil)-1,3-dihidro-izobenzofuran-1-il]-propil}-N-metil glicin
ili njihove farmaceutski prihvatljive kiselinske soli.
Ovaj izum daje farmaceutsku smjesu koja sadrži bar jedan spoj formule I prema gornjoj definiciji ili njegovu farmaceutski prihvatljivu kiselinsku sol u terapeutski djelotvornoj količini i u kombinaciji s jednim ili više farmaceutski prihvatljivih nositelja ili razrjeđivača.
Ovaj izum, osim toga, nudi uporabu gornjih spojeva za proizvodnju lijekova za liječenje bolesti koje reagiraju na ligande prijenosnika glicina.
Ovaj izum nudi i način liječenja bolesti koje reagiraju na ligande prijenosnika glicina.
U preferiranim varijantama ovog izuma, ligandi su antagonisti prijenosnika glicina.
Farmaceutski prihvatljive kiselinske soli su one koje tvore farmaceutski prihvatljive anione, poput maleinske, fumarne, benzojeve, askorbinske, jantarne, oksalne, bi-metilensalicilne, metansulfonske, etandisulfonske, octene, propionske, vinske, salicilne, limunske, glukonske, mliječne, jabučne, bademove, cinamične, citrakonske, asparaginske, stearinske, palmitinske, itakonske, glikolne, p-aminobenzojeve, glutaminske, benzensulfonske i teofilinske octene kiseline, kao i 8-haleofilina, na primjer 8-bromoteofilina. Primjeri takvih anorganskih soli su one sa solnom, hidrobromnom, sumpornom, sulfaminskom, fosfornom i dušičnom kiselinom.
Spoj prema ovom izumu može se primjenjivati na bilo koji prikladan način poput oralnog ili parenteralnog, a može biti u bilo kojem obliku prikladnom za takvu primjenu, na primjer u obliku tableta, kapsula, prašaka, sirupa ili otopina ili disperzija za ubrizgavanje. Preferirano, i u skladu sa svrhom ovog izuma, spoj prema ovom izumu primjenjuje se u obliku krute farmaceutske tvorevine, prikladno kao tableta ili kapsula, ili u obliku suspenzije, otopine ili disperzije za ubrizgavanje.
Načini priprave krutih farmaceutskih pripravaka dobro su poznati struci. Tako se tablete mogu pripravljati miješanjem aktivnih tvari s običnim pomoćnim tvarima i/ili razrjeđivačima te potom komprimiranjem mješavine u konvencionalnom stroju za tabletiranje. Primjeri pomoćnih tvari ili razrjeđivača su: škrobno brašno, laktoza, talk, magnezijev stearat, želatina, laktoza, vezivna sredstva i slično. Može se rabiti bilo koje drugo pomoćno sredstvo ili aditiv, poput boje, arome, konzervansa itd., pod uvjetom da bude kompatibilno s aktivnim tvarima.
Osim toga, spojevi prema ovom izumu mogu biti u netopivom kao i topivom obliku s farmaceutski prihvatljivim otapalima poput vode, etanola i sličnog. Općenito, za svrhe ovog izuma topivi se oblici smatraju ekvivalentom netopivih.
Neki od spojeva prema ovom izumu sadrže hiralne centre i takvi se spojevi javljaju u obliku izomera (npr. enantiomera). Ovaj izum uključuje sve takve izomere i bilo kakve njihove mješavine uključujući racemične mješavine.
Racemični oblici mogu se u optičke antipode pretvoriti na poznate načine, na primjer separacijom njihovih dijastereometričkih soli s optički aktivnom kiselinom i oslobađanjem spoja optički aktivnog amina tretiranjem s bazom. Drugi način pretvaranja racemata u optičke antipode temelji se na kromatografiji na optički aktivnoj matrici. Tako se racemični spojevi prema ovom izumu mogu pretvoriti u njihove optičke antipode npr. frakcionalnom kristalizacijom d- ili 1- (tartratnih, mandelatnih ili kamforsulfonatnih) soli.
Spojevi prema ovom izumu mogu se također pretvoriti i stvaranjem dijastereomeričkih derivata.
Za pretvaranje optičkih izomera mogu se primijeniti i drugi načini, poznati stručnjacima. Ti načini uključuju i one o kojima govore J. Jaques, A. Collet i S. Wilen u "Enantiomers, Racemtaes, and Resolutions", John Wiley and Sons, New York (1981.).
Optički aktivni spojevi mogu se pripraviti i iz optički aktivnih polaznih supstanci.
Definicija supstituenata
Halogen znači fluor, klor, brom ili jod. Preferirani halogeni su F i Cl.
Izraz C1-6-alkil odnosi se na razgranatu ili nerazgranatu alkilnu skupinu koja ima jedan do uključivo šest atoma ugljika, poput metila, etila, 1-propila, 2-propila, 1-butila, 2-butila, 2-metil-2-propila i 2-metil-1-propila. Preferirani metili su metil i etil.
Slično tome, C2-6-alkenil odnosno C2-6-alkinil označavaju skupine koje imaju od dva do šest atoma ugljika, uključujući jednu dvostruku odnosno trostruku vezu, poput etenila, propenila, butenila, etinila, propinila i butinila.
Izraz C3-8-cikloalkil označava monociklični ili biciklični C-prsten koji ima tri do osam atoma ugljika, poput ciklopropila, ciklopentila, cikloheksila itd.
Izraz C3-8-cikloalkilalkil označava cikloalkil prema gornjoj definiciji i alkil prema gornjoj definiciji.
Izrazi C1-6-alkoksi i C1-6-alkitio označavaju skupine u kojima je alkilna skupina C1-6-alkil prema gornjoj definiciji.
Izraz aril označava aromatski ugljikovodik poput fenila ili naftila.
Izraz heteroaril odnosi se na mono- ili biciklične heterociklične aromatske skupine koje sadrže bar jedan N, S ili O atom, poput furila, pirolila, tienila, oksazolila, izoksazolila, tiazolila, izotiazolila, imidazolila, piridila, pirimidila, tetrazolila, benzofuranila, benzotienila, benzimidazolila, indolila. Preferirani heteroarili su monociklični heteroarili. Posebno je preferiran tienil.
Primjeri pripravljanja
Spojevi prema ovom izumu mogu se pripraviti kako slijedi:
1) alkilacijom amina formule II s alkilirajućim agensom formule I
G je prikladni ostatak poput npr. halogena ili mesilata.
[image]
supstituenti R1-R12, n, Y i X su prema ranijoj definiciji;
2) alkilacijom amina formule III s alkilirajućim agensom formule IV
[image]
u kojoj su supstituenti R1-R12, n, Y i X prema ranijoj definiciji;
kopulacijom supstituenta arila formule VI s derivatom aril bromida formule V, u kojoj su supstituenti R4-R7 halogeni, R1-R3 i R8-R12, n, Y i X prema ranijoj definiciji
[image]
4) hidrolizom skupine estera spoja iz formule VII kako bi se dobio odgovarajući derivat karboksilne kiseline
[image]
supstituenti R1-R12, n i Y su prema ranijoj definiciji, a X je OH u finalnom proizvodu.
Alkilacije prema načinima 1 i 2 prikladno se provode u intertnom otapalu poput prikladno kipućeg alkohola ili ketona ili u tetrahidrofuranu, preferirano uz prisutnost organske ili anorganske baze (kalijev karbonat, diizopro-piletilamin ili trietilamin) na temperaturi refluksa. Alternativno, alikilacija se može provesti na fiksnoj temperaturi koja je različita od vrelišta u jednom od gore spomenutih otapala ili u dimetilformamidu, dimetilsulfoksidu ili N-metilpirolidinu-2-jedan, preferirano uz prisutnost baze.
Reagensi formule I pripravljaju se na načine opisane u literaturi, vidi npr. US 3,549,656, GB 1166711 i Dykstra i sur. J. Med. Chem. 1967., 10(3), 418-28.
Derivati glicina formule II dobro su opisani u literaturi.
Amini formule III pripravljaju se prema opisu u Bigler i sur. Eur. J. Med. Chem. 1977., 12, 289.
Derivati biarila formule IV pripravljaju se suzuki tipom kopuliranja aril boronske kiseline sa željenim halidom u dimetoksietanu, tetrahidrofuranu ili toluenu koji sadrže anorgansku bazu poput natrijevog karbonata i paladijev katalizator, na temperaturi između sobne temperature i vrelišta otapala.
Hidroliza prema načinu 4 prikladno se provodi u primjereno kipućem alkoholu uz prisutnost u vodi otopljene baze poput npr. natrijevog hidroksida, na sobnoj temperaturi. Polazne supstance formule V pripravljaju se na načine 1 ili 2.
Pokusi
Tališta su određivana na uređaju Büchi SMP-20 i nisu korigirana. Analitički LC-MS podaci dobiveni su na instrumentu PE Sciex API 150EX opremljenom IonSpray izvorom i Shimadzu LC-8A/SLC-10A LC sustavom. LC uvjeti (50 X 4,6 mm YMC ODS-A s veličinom čestica 5 μm) bili su linearna gradientna elucija s vodom/acetonitrilom/trifluorooctenom kiselinom (90:1=.0,05) u vodu/acetonitril/trifluorooctenu kiselinu (10:90:0,03) za 7 min pri 2mL/min. Čistoća je određivana integracijom UV traga (254 nm). Vremena retencije, Rt, izražena su u minutama.
Maseni spektri dobiveni su alternirajućom metodom skeniranja koja daje podatke o molekularnoj težini. Molekularni ion, MH+, dobiven je pri niskoj voltaži otvora (5-20V), a fragmentacija pri visokoj voltaži otvora (100V).
Preparativna LC-MS-separacija provedena je na istom istrumentu. LC uvjeti (50 X 20 mm YMC ODS-A s veličinom čestica 5 μm) bili su gradijentna elucija s vodom/acetonitrilom/trifluorooctenom kiselinom (80:20:0,05) u vodu/acetonitril/trifluorooctenu kiselinu (10:90:0,03) za 7 min pri 11,7 mL/min. Prikupljanje frakcije provedeno je "split-flow" MS detekcijom.
1H NMR spektri zabilježeni su pri 500,13 MHz na instrumentu Bruker Avance DRX500 ili pri 250,13 MHz na instrumentu Bruker AC 250. Kao otapala rabili su se deuterizirani kloroform (99,8%D) ili dimetil sulfoksid (99,9%D).TMS je korišten kao interni referentni standard. Vrijednosti kemijskih pomaka izražene su u ppm-vrijednostima. Za multiplicitet NMR signala koriste se sljedeće kratice: s=singlet, d=dublet, t=triplet, q=kvartet, qui=kvintet, h=heptet,dd=dvostruki dublet, dd=dvostruki triplet, dq=dvostruki kvartet, tt= trostuki triplet, m=multiplet, b=prošireni singlet. NMR signali koji odgovaraju kiselinskim protonima općenito su izostavljeni. Sadržaj vode u kristaliziranim sastojcima određen je Karl Fischerovom titracijom. Standardni procesi obrade odnose se na ekstrakciju s naznačenim organskim otapalom iz pravih vodenih otopina, sušenje kombiniranih organskih ekstrakta (bezvodni MgSO4 ili NaSO4), filtriranje i uparavanje otapala in vacuo. Za kromatografiju u koloni korišten je silikagel tipa Kieselgel 60, 230-400 mesh ASTM. Za kromatografiju ionskom izmjenom korišten je SCX, 1 g, Varian Mega Bond Elut®, Chrompack kat. br. 220776. Prije uporabe SCX-kolona je prekondicionirana 10%-tnom otopinom octene kiseline u metanolu (3 mL).
Sljedeći primjeri još će bolje ilustrirati ovaj izum. Međutim, ne treba ih smatrati ograničavajućima.
Primjeri
Primjer 1
1a, N-(3-(5-Cijano-1-(4-fluorofenil)-1,3-dihidroizobenzofuran-1-il)-1-propil) glicine.etil ester
Miješana mješavina 3-(5-cijano-1-(-4-fluorofenil)-1,3-dihidroizobenzofuran-1-il)-1-propil amina (1,5 g), kalijevog karbonata (1,3 g) i etanola (15 mL) kap po kap je tretirana otopinom etil bromoacetata (0,75 g) u etanolu (15 mL) na sobnoj temperaturi. Nakon refluksa od 1,5 h, mješavina je ohlađena i koncentrirana in vacuo. Standardna obrada etil acetatom dala je ulje koje je pročišćeno flash kromatografijom (eluent heptan/etil acetat/trietilamin 26:70:4). Spoj iz naslova dobiven je u obliku bistrog ulja (0,77 g). LC/MS (m/z) 383 (MH+), čistoća (UV): >99%.
Primjer 2
2a, N-(3-(5-Cijano-1-(4-fluorofenil)-1,3-dihidroizobenzofuran-1-il)-1-propil)-N-metilglicin.etil ester
Miješana mješavina 3-(5-cijano-1-(4-fluorofenil)-1,3-dihidroizobenzofuran-1-il)-1-propil jodida (3,1 g), etil N-metilglicinata (4,4 g) i dietilizopropilamina (4,4 g) u tetrahidrofuranu (50 mL) 16 je sati bila pod refluksom. Standardna obrada etil acetatom dala je ulje koje je pročišćeno flash kromatografijom (eluent heptan/etil acetat/trietilamin 64:32:4) te je nastao spoj iz naslova u obliku bistrog ulja (1,4 g).
LC/MS (m/z) 397 (MH+), čistoća (UV): >99%.
Primjer 3
3a, N-(3-(5-Cijano-1-(4-fluorofenil)-1,3-dihidroizobenzofuran-1-il)-1-propil) glicin hidroklorid
Mješavina N-(3-(5-cijano-1-(4-fluorofenil)-1,3,-dihidroizobenzofuran-1-il)-1-propil)glicinetil estera (0,7 g), metanola (6 mL) i 6 M natrijevog hidroksida (2 mL) miješana je 2 h na sobnoj temperaturi. Podešavanjem pH na < 6,5 otopljenom solnom kiselinom, a potom standardnom obradom etil acetatom dobiven je spoj iz naslova u obliku ulja (0,2 g).
LC/MS (m/z) 355 (MH+), čistoća (UV): >90%.
Na sličan su način pripravljeni i sljedeći spojevi:
3b, N-(3-(5-Cijano-1-(4-fluorofenil)-1,3-dihidrpoizobenzofuran-1-il)-1-propil)-N-metilglicin hidroklorid
LC/MS 8m/z) 369 (MH+), čistoća (UV): >90%
3c, primjer 4:
N-{3-[1-(3-klorofenil)-1,3-dihidroizobenzofuran-1il]-1-propil}-N-metilglicin hidroklorid
LC/MS (m/z) 360 (MH+), čistoća (UV 90%)
3d, primjer 5:
N-{3-[1-(3-trifluorometilfenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin hidroklorid
LC/MS (m/z) 394 (MH+), čistoća (UV 79%)
3e, primjer 6:
N-{3-[1-(3-trifluorometilfenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metil(1-etil)glicin hidroklorid
LC/MS (m/z) 422 (MH+), čistoća (UV 79%)
3f, primjer 7:
N-{3-[1-(4-metilfenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin hidroklorid
LC/MS (m/z) 378 (MH+), čistoća (UV 91%)
3g, primjer 8:
N-{3-[1-(4-fluorofenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin hidroklorid
LC/MS (m/z) 344 (MH+), čistoća (UV 81%)
3h, primjer 9:
N-{3-[1-(4-fluorofenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilalanin hidroklorid
LC/MS (m/z) 358 (MH+), čistoća (UV 81%)
3i, primjer 10
N-{3-[1-(4-fluorofenil(-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metil(1-etil)glicin hidroklorid
LC/MS (m/z) 372 (MH+), čistoća (UV 86%)
3j, primjer 11
N-{3-[4-kloro-1-(3-metil-4-fluorofenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin hidroklorid
LC/MS (m/z) 392 (MH+), čistoća UV 86%)
3k, primjer 12
N-{3-[4-kloro-1-(4-klorofenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin hidroklorid
LC/MS (m/z) 394 (MH+), čistoća (UV 98%)
3l, primjer 13
N-{3-[5-kloro-1-(4-klorofenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilalanin hidroklorid
LC/MS (m/z) 408, čistoća (UV 85%)
3m, primjer 14
N-{3-[6-kloro-1-(4-klorofenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin hidroklorid
LC/MS(m/z) 394 (MH+), čistoća (UV 99%)
3n, primjer 15
N-{3-[6-kloro-1-(4-metilfenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin hidroklorid
LC/MS (m/z) 374 (MH+), čistoća (UV 76%)
3o, primjer 16
N-{3-[6-kloro-1-(4-metoksifenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin hidroklorid
LC/MS (m/z) 390 (MH+), čistoća (UV 98%)
3p, primjer 17
N-{3-[5-(fluoro-1-(4-klorofenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin hidroklorid.
LC/MS (m/z) 378 (MH+), čistoća (UV 85%)
3q, primjer 18
N-{3-[5-fluoro-1-(4-metoksifenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin hidroklorid
LC/MS (m/z) 378 (MH+), čistoća (UV 99%)
3r, primjer 19
N-{3-[5-trifluorometil-1-(4-fluorofenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin hidroklorid
LC/MS (m/z) 412 (MH+), čistoća (UV 81%)
3s, primjer 20
N-{3-[5-trifluorometil-1-(4-fluorofenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilalanin hidroklorid
LC/MS (m/z) 426 (MH+), čistoća (UV 98%)
3t, primjer 21
N-{3-[5-cijano-1-(3-metil-4-fluorofenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin hidroklorid
LC/MS (m/z) 383 (MH+), čistoća (UV 83%)
3u, primjer 22
N-{3-[5-cijano-1-(cijanofenil)-indan-1-il]-1-propil}-N-metilalanin hidroklorid
LC/MS /m/z) 388 (MH+), čistoća (UV 80%)
3v, primjer 23
N-{3-[5-cijano-1-(4-metoksifenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin hidroklorid
LC/MS (m/z) 381 (MH+), čistoća (UV 81%)
3x, primjer 24
N-{3-[5-cijano-1-(4-fluorofenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin hidroklorid
LC/MS (m/z) 369 (MH+), čistoća (UV 98%)
3y, primjer 25
N-{2-[5-cijano-1-(4-fluorofenil)-1,3-dihidroizobenzofuran-1-il]etil}-N-metilglicin hidroklorid
LC/MS (m/z) 355 (MH+), čistoća (UV 94%)
3z, primjer 26
N-{3-[5-Kloro-1-(4-kloro-fenil)-indan-1-il]-propil}-N-metilglicin hidroklorid
LC/MS (m/z) 392 (MH+), čistoća (UV 98%)
3aa, primjer 27
N-{3-[5-Kloro-1-(4-kloro-fenil)-indan-1-il]-propil}-N-metilalanin hidroklorid
LC/MS (m/z) 406 (MH+), čistoća (UV 95%)
3ab, primjer 28
N-{3-[3-spirociklopentil-1-(4-metilfenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin hidroklorid
3ac, primjer 29
N-[3-(3,3-Dimetil-1-fenil-1,3-dihidro-benzo[c]tiofen-1-il)-propil]-N-metilglicin hidroklorid
3ad, primjer 30
N-[3-(3,3-Dimetil-1-fenil-1,3-dihidro-benzo[c]tiofen-1-il)]propil-N-metilalanin
LC/MS (m/z) 370, Čistoća (UV 96%)
3ae, primjer 32
N-{3-[5-Bromo-1-(4-klorofenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin
LC/MS (m/z) 440 (MH+), čistoća (ELSD 93%)
3af, primjer 33
N-{2-[1-(4-Kloro-fenil)-3,3,-dimetil-1,3-dihidro-izobenzofuran-1-il]-etil}-N-metilglicin
LC/MS (m/z) 374 (MH+), čistoća (UV 72%)
3ag, primjer 34
N-[3-(3-metil-1-fenil-1H-inden-1-il)-propil]-N-metilglicin
LC/MS (m/z) 336 (MH+), čistoća (UV 85%)
3ah, primjer 35
N-[3-(5-Kloro-1-tiofen-2-il-1,3-dihidro-izobenzofuran-1-il)-propil]-N-metilalanin
LC/MS (m/z) 380 (MH+), čistoća (UV 85%)
3ai, primjer 26
N-[3-(5-Kloro-1-tiofen-2-il-1,3-dihidro-izobenzofuran-1-il)-propil]-N-metil(1-etil)-glicin
LC/MS (m/z) 394 (MH+), čistoća (UV 80%)
3aj, primjer 37
N-[3-(3-metil-1-fenil-1,3-dihidro-izobenzofuran-1-il)-propil]-N-metilalanin
LC/MS (m/z) 354 (MH+), čistoća (UV 78%)
3ak, primjer 38
N-[2-(3-metil-1-fenil-indan-1-il)-etil]-amino}-N-metil alanin
LC/MS (m/z) 451, čistoća (UV 92%)
3al, primjer 39
N-{3-[1-(4-Kloro-fenil)-5-(4-metil-fenil)-1,3-dihidro-izobenzofuran-1-il]-etil}-N-metil-glicin
Primjer 4
4a, N-{3-[5-Bromo-kloro-1-(4-klorofenil)-1,3-dihidroizobenzofuran-1-il]-1-etil}-N-metilglicin etil ester (226 mg, 0,5 mmol) otopljen je u 1:1 mješavini tetrahidrofurana i dimetoksietana (3 mL) koja sadrži tetrakis (trifenilfosfin) paladij, u atmosferi dušika. Reakciji je dodan 4-klorofenil boronska kiselina (102 mg, 0,75 mmol) i 0,5M vodene otopine natrijevog karbonata (2 mL), 1 mmol), te je reakcija 18 sati grijana na 65°C. Otopina je razrijeđena vodom (5 mL) i etil acetatom (7 mL). Organski sloj je separiran, a vodeni sloj je ponovno ekstrahiran etil acetatom (5 mL). Organski ekstrakti su kombinirani i isprani zasićenom otopinom matičnog luga (7 mL) prije uparavanja uz prisutnost 1 g silikagela. Sirovi proizvod apsorbiran na silikagelu preliven je preko punjenja od 20 g silikagela i eluiran na sustavu gradijentnih otapala eluirajući se iz heptana u heptan/etil acetat (1:1) preko 37 minuta. Proizvod je izoliran kao lako ulje (135 mg, 64%). LC/MS 479.
Spoj je hidroliziran prema opisu za Primjer 3a te je dobiven derivat N-metilglicin hidroklorida.
LC/MS (m/z) 436, čistoća (UV 92%).
Na sličan način pripravljeni su sljedeći spojevi:
4b, primjer 40
N-{3-[1-(4-Kloro-fenil)-5-(4-metoksi-fenil)-1,3-dihidro-izobenzofuran-1-il]-etil}-N-metil-glicin
LC/MS (m/z) 452, čistoća (UV 94%)
4c, primjer 41
N-{3-[1-(4-Kloro-fenil)-5-(2-tiofenil)-1,3-dihidro-izobenzofuran-1-il]-etil}-N-metil-glicin
LC/MS (m/z) 428m čistoća (UV 96%)
4d, primjer 42
N-{3-[1-(4-Kloro-fenil)-5-(4-metil-fenil)-1,3-dihidro-izobenzofuran-1-il]-propil}-N-metil-glicin
LC/MS (m/z) 450, čistoća 91%
4e, primjer 43
N-{3-[1-(4-Kloro-fenil)-5-(4-metoksi-fenil)-1,3-dihidro-izobenzofuran-1-il]-propil}-N-metil-glicin
LC/MS (m/z) 466, čistoća (UV 95%)
4f, primjer 44
N-{3-[1-(4-kloro-fenil)-5-(4-trifluorometil-fenil)-1,3-dihidro-izobenzofuran-1-il]-propil}-N-metil-glicin
LC/MS (m/z) 504, čistoća (UV 89%)
4g, primjer 45
N-{3-[1-(4-Kloro-fenil)-5-(4-kloro-fenil)-1,3-dihidro-izobenzofuran-1-il]-etil}-N-metil-glicin
LC/MS (m/z) 456, čistoća 96%
4h, primjer 46
N-{2-[1-(4-Kloro-fenil)-5-(5-kloro-tiofen-2-il)-1,3-dihidro-izobenzofuran-1-il]-etil}-N-metil-glicin
LC/MS (m/z) 462, čistoća 74%
4i, primjer 47
N-{3-[1-(4-Kloro-fenil)-5-(3-metil-fenil)-1,3-dihidro-izobenzofuran-1-il]-etil}-N-metil-glicin
LC/MS (m/z) 436, čistoća 94%
4j, primjer 48
N-{3-[1-(4-Kloro-fenil)-5-(2-metil-fenil)-1,3-dihidro-izobenzofuran-1-il]-etil}-N-metil-glicin
LC/MS (m/z) 436, čistoća (UV 91%)
4k, primjer 49
N-{3-[1-(4-Kloro-fenil)-5-(2,5-dikloro-fenil)-1,3-dihidro-izobenzofuran-1-il]-etil}-N-metil-glicin
LC/MS (m/z) 490, čistoća 94%
4l, primjer 50
N-{3-[1-(4-kloro-fenil)-5-(3-trifluorometil-fenil)-1,3-dihidro-izobenzofuran-1-il]-etil}-N-metil-glicin
LC/MS (m/z) 490, čistoća 89%
4m, primjer 51
N-{3-[1-(4-kloro-fenil)-5-(3-trifluorometil-fenil)-1,3-dihidro-izobenzofuran-1-il]-propil}-N-metil-glicin
LC/MS (m/z) 506, čistoća 91%
4n, primjer 52
N-{3-[1-(4-Kloro-fenil)-5-(3,4-dikloro-fenil)-1,3-dihidro-izobenzofuran-1-il]-etil}-N-metil-glicin
LC/MS (m/z) 490, čistoća 89%
4o, primjer 53
N-{3-[1-(4-Kloro-fenil)-5-(4-kloro-fenil)-1,3-dihidro-izobenzofuran-1-il]-propil}-N-metil-glicin
LC/MS (m/z) 470, čistoća (UV 94%)
4p, primjer 54
N-{3-[1-(4-Kloro-fenil)-5-(3-metil-fenil)-1,3-dihidro-izobenzofuran-1-il]-propil}-N-metil-glicin
LC/MS (m/z) 450, čistoća 96%
4q, primjer 55
N-{3-[1-(4-Kloro-fenil)-5-(2-metil-fenil)-1,3-dihidro-izobenzofuran-1-il]-propil}-N-metil-glicin
LC/MS (m/z) 450, čistoća 93%
4r, primjer 56
N-{3-[1-(4-Kloro-fenil)-5-(2,5-dikloro-fenil)-1,3-dihidro-izobenzofuran-1il]-propil}-N-metil-glicin
LC/MS (m/z) 506, čistoća 91%
4s, primjer 57
N-{3-[1-(4-Kloro-fenil)-5-(3,4-dikloro-fenil)-1,3-dihidro-izobenzofuran-1-il]-propil}-N-metil-glicin
LC/MS (m/z) 504, čistoća 95%
4t, primjer 58
N-{3-[1-(4-kloro-fenil)-5-(2-trifluorometil-fenil)-1,3-dihidro-izobenzofuran-1-il]-propil}-N-metil-glicin
LC/MS (m/z) 504, čistoća 78%
Farmakološka ispitivanja
Spojevi prema ovom izumu ispitani su u vrlo priznatim i pouzdanim testovima kojima se mjeri preuzimanje glicina:
Preuzimanje [3H]-glicina
Stanice u koje je bio prenesen ljudski GlyT-1b stavljene su u 96 posudica. Prije pokusa stanice su dvaput isprane u HBS (10 nM Hepes-tris (pH 7,4), 2,5 mK KCl, 1 mM CaCl2, 2,5 mM MgSO4) i 6 minuta predinkubirane ispitivanim spojem. Nakon toga, u svaku je posudicu dodano 10 nM 3H-glicina i inkubacija je nastavljena još 15 minuta. Stanice su dvaput isprane u HBS. Dodana je svjetlucava tekućina i posudice su potom ispitane pomoću Trilux (Wallac) uređaja za brojanje iskrenja.
Rezultati ispitivanja bili su sljedeći:
Inhibicija prijenosa glicina putem hGlyT-
Spoj Naziv spoja IC50 GlyT-1b
3f N-{3-[1-(4-metilfenil)-1,3-dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin 5400
3k N-{3-[4-kloro-1-(4-klorofenil)-1,3- dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin 4100
3l N-{3-[5-kloro-1-(4-klorofenil)-1,3- dihidroizobenzofuran-1-il]-1-propil}-N-metilalanin 5500
3m N-{3-[6-kloro-1-(4-klorofenil)-1,3- dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin 7200
3n N-{3-[6-kloro-1-(4-metilfenil)-1,3- dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin 9600
3t N-{3-[5-cijano-1-(3-metil-4-fluorofenil)-1,3- dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin 5700
3v N-{3-[5-cijano-1-(4-metoksifenil)-1,3- dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin 8600
3z N-{3-[5-Kloro-1-(4-kloro-fenil)-indan-1-il]-propil}-N-metilalanin 1100
3aa N{3-[5-Kloro-1-(4-kloro-fenil)-indan-1-il]-propil}-N-metilalanin 470
3ae N-{3-[5-Bromo-1-(4-klorofenil)-1,3- dihidroizobenzofuran-1-il]-1-propil}-N-metilglicin 4000
3af N-{2-[1-(4-Kloro-fenil)-3,3-dimetil-1,3-dihidro-izobenzofuran-1-il]-etil}-N-metilglicin 3500
3ak N-[2-(3-metil-1-fenil-indan-1il)-etil]-amino}-N-metil alanin 2200
3al N-{3-[1-(4-Kloro-fenil)-5-(4-metil-fenil)-1,3-dihidro-izobenzofuran-1-il]-etil}-N-metil-glicin 2200
4c N-{3-[1-(4-Kloro-fenil)-5-(2-tiofenil)-1,3-dihidro-izobenzofuran-1-il]-etil}-N-metil-glicin 1200
4d N-{3-[1-(4-Kloro-fenil)-5-(4-metil-fenil)-1,3-dihidro-izobenzofuran-1-il]-propil}-N-metil-glicin 1500
4j N-{3-[1-(4-Kloro-fenil)-5-(2-metil-fenil)-1,3-dihidro-izobenzofuran-1-il]-etil}-N-metil-glicin 710
4k N-{3-[1-(4-Kloro-fenil)-5-(2,5-dikloro-fenil)-1,3-dihidro-izobenzofuran-1-il]-etil}-N-metil-glicin 950
Gornji rezultati pokazuju da su spojevi prema ovom izumu sposobni inhibirati preuzimanje glicina u sinaptosome u mikromolarnim koncentracijama.
Claims (15)
1. Spoj naznačen time da je predstavljen općom formulom I
[image]
u kojoj
R1 predstavlja vodik, C1-6-alkil, cikloalkil ili cikloalkilalkil;
R2 i R3 neovisno predstavljaju vodik, halogen, C1-6-alkil, C3-8-cikloalkil ili C3-8-cikloalkil-C1-6-alkil ili R2 i R3 zajedno tvore C3-8-cikloalkil;
R4, R5, R6 i R7 neovisno predstavljaju vodik, halogen, CF3, NO2, CN, C1-6-alkil, C2-6-alkenil, C2-6-alkinil, C3-8-cikloalkil, C1-6-alkoksi, C1-6-alkitio, OH, SH, NR14R15, pri čemu R14 i R15 neovisno predstavljaju vodik ili C1-6-alkil; -COR16 gdje R16 predstavlja OH, C1-6-alkil, C1-6-alkoksi, NR17R18, gdje R17 i R18 neovisno predstavljaju vodik ili C1-6-alkil; aril ili heteroaril, pri čemu su aril i heteroaril opcionalno jednom ili više puta supstituirani halogenom, CF3, OCF3, CN, NO2, C1-6-alkilom, C2-6-alkenilom, C2-6-alkinilom, C3-8-cikloalkilom, C1-6-alkoksi, C1-6-tioalkil, OH, SH ili NR24R25, gdje R24 i R25 neovisno predstavljaju vodik ili C1-6-alkil;
ili R4 i R5 ili R5 i R6 ili R6 i R7 zajedno tvore kondenziran, aromatski, zasićen ili djelomično zasićen prsten koji opcionalno sadrži jedan ili više heteroatoma poput O, N ili S;
R8, R9, R10, R11 i R12 neovisno predstavljaju vodik, CF3, OCF3, CN, NO2, C1-6-alkil, C2-6-alkenil, C2-6-alkinil, C3-8-cikloalkil, C1-6-alkoksi, C1-6-alkitio, OH, SH, NR19R20, gdje R19 i R20 neovisno predstavljaju vodik ili C1-6-alkil; ili R8, R9, R10, R11 i R12 neovisno predstavljaju –COR21, gdje R21 predstavlja OH, C1-6-alkoksi, NR22R23 gdje R22 i R23 neovisno predstavljaju vodik ilii C1-6-alkil; ili R8, R9, R10, R11 i R12 neovisno predstavljaju aril ili heteroaril, s time da su aril i heteroaril opcionalno jednom ili više puta supstituirani halogenom, CF3, OCF3, CN, NO2, C1-6-alkilom, C2-6-alkenilom, C2-6-alkinilom, C3-8-cikloalkilom, C1-6-alkoksi, C1-6-alkitio, OH, SH, COR26, gdje R26 predstavlja OH, C1-6-alkoksi ili C1-6-alkil; ili NR30R31, gdje R30 i R31 neovisno predstavljaju vodik ili C1-6-alkil;
R8 i R9 ili R9 i R10 ili R10 i R11 ili R11 i R12 zajedno tvore kondenziran, aromatski, zasićen ili djelomično zasićen prsten koji opcionalno sadrži jedan ili više heteroatoma poput O, N ili S;
Y je O, S, CH2 ili CH, a kad Y znači CH točkasta crta predstavlja vezu;
n je 2, 3, 4, 5 ili 6;
Q predstavlja C, P-OR29 ili S=O, gdje R29 predstavlja vodik ili C1-6-alkil, aril ili aril-C1-6-alkil, pri čemu aril može biti supstituiran halogenom, CF3, OCF3, CN, NO2 ili C1-6-alkilom; opcionalno R27 i R28 zajedno tvore prsten koji može sadržavati još atoma dušika, kisika i sumpora, a prsten može opcionalno biti djelomično zasićen;
R29 i R30 predstavljaju vodik, C1-6-alkil, cikloalkil ili cikloalkilalkil;
ili njihove farmaceutski prihvatljive soli.
2. Spoj prema prethodnom patentnom zahtjevu, naznačen time da n predstavlja 2 ili 3.
3. Spoj prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da R1 predstavlja CH3.
4. Spoj prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da Q znači C,
5. Spoj prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da X predstavlja OH ili C1-6-alkoksi.
6. Spoj prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da R7 predstavlja vodik, a R4, R5 ili R6 predstavljaju vodik, C1-6-alkil, CN, halogen, CF3 ili fenil opcionalno jednom ili više puta supstituiran halogenom, C1-6-alkilom, C1-6-alkoksi, CF3 ili R4, R5 i R6 predstavljaju heteroaril opcionalno jednom ili više puta supstituiran halogenom ili R4 i R5 ili R5 i R6 zajedno tvore kondenziran prsten.
7. Spoj prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da R8, R9, R10, R11 i R12 neovisno predstavljaju vodik, halogen, alkil, alkoksi ili R8 i R9 ili R9 i R10 zajedno tvore kondenziran aril.
8. Spoj prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da R8, R9, R10, R11 ili R12 neovisno predstavljaju vodik, C1-6-alkil, C1-6-alkoksi.
9. Farmaceutska smjesa naznačena time da sadrži bar jedan spoj prema bilo kojem od prethodnih patentnih zahtjeva, ili njihovu farmaceutski prihvatljivu kiselinsku sol, u terapeutski djelotvornoj količini i u kombinaciji s jednim ili više farmaceutski prihvatljivih nositelja ili razrjeđivača.
10. Uporaba spoja prema patentnim zahtjevima 1-8, naznačena time da je za proizvodnju lijeka za liječenje bolesti koje reagiraju na modulaciju prijenosnika glicina.
11. Uporaba prema patentnom zahtjevu 10, naznačena time da bolest reagira na antagonizam prijenosnika glicina.
12. Uporaba prema patentnim zahtjevima 10 i 11, naznačena time da je bolest odabrana iz skupine koja se sastoji od pozitivnih i negativnih simptoma shizofrenije, psihoza, demencije, boli, poboljšanja shvaćanja, Alzheimerove bolesti, multi-infarktne demencije, demencije uzrokovane AIDS-om, Huntingtonove bolesti, Parkinsonove bolesti, amiotropne lateralne skleroze ili bolesti u kojima je mozak oštećen uslijed unutrašnjeg ili vanjskog utjecaja, poput traume glave ili moždanog udara.
13. Način liječenja bolesti koja reagira na modulaciju prijenosnika glicina, naznačen time da se bolesniku kojemu je to potrebno daje djelotvorna količina spoja prema patentnim zahtjevima 1-8.
14. Način prema patentnom zahtjevu 13, naznačen time da bolesti reagiraju na antagonizam prijenosnika glicina.
15. Način prema patentnim zahtjevima 13 i 14, naznačen time da su bolesti koje će se liječiti izabrane iz skupine koja se sastoji od pozitivnih i negativnih simptoma shizofrenije, psihoza, demencije, boli, poboljšanja shvaćanja, Alzheimerove bolesti, multi-infarktne demencije, demencije uzrokovane AIDS-om, Huntingtonove bolesti, Parkinsonove bolesti, amiotropne lateralne skleroze ili bolesti u kojima je oštećen mozak uslijed unutrašnjih ili vanjskih utjecaja, poput traume glave ili moždanog udara.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200001124 | 2000-07-21 | ||
PCT/DK2001/000510 WO2002008216A1 (en) | 2000-07-21 | 2001-07-19 | Novel compounds and their use as glycine transport inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20030053A2 true HRP20030053A2 (en) | 2005-02-28 |
Family
ID=8159626
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20030053A HRP20030053A2 (en) | 2000-07-21 | 2003-01-27 | Novel compounds and their use as glycine transport inhibitors |
Country Status (28)
Country | Link |
---|---|
US (1) | US6921774B2 (hr) |
EP (1) | EP1301502B1 (hr) |
JP (1) | JP2004504393A (hr) |
KR (1) | KR20030015889A (hr) |
CN (1) | CN100509791C (hr) |
AR (1) | AR032358A1 (hr) |
AT (1) | ATE295844T1 (hr) |
AU (2) | AU2001281740B2 (hr) |
BG (1) | BG107530A (hr) |
BR (1) | BR0113011A (hr) |
CA (1) | CA2416447A1 (hr) |
CZ (1) | CZ2003396A3 (hr) |
DE (1) | DE60110914T2 (hr) |
EA (1) | EA005621B1 (hr) |
ES (1) | ES2238466T3 (hr) |
HR (1) | HRP20030053A2 (hr) |
HU (1) | HUP0302778A3 (hr) |
IL (2) | IL153988A0 (hr) |
IS (1) | IS6693A (hr) |
MX (1) | MXPA03000642A (hr) |
NO (1) | NO20030243L (hr) |
NZ (1) | NZ523720A (hr) |
PL (1) | PL364439A1 (hr) |
PT (1) | PT1301502E (hr) |
SK (1) | SK2022003A3 (hr) |
UA (1) | UA75081C2 (hr) |
WO (1) | WO2002008216A1 (hr) |
ZA (1) | ZA200300514B (hr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004233942A1 (en) * | 2003-04-30 | 2004-11-11 | H. Lundbeck A/S | Aromatic oxyphenyl and aromatic sulfanylphenyl derivatives |
KR20060066729A (ko) * | 2003-08-21 | 2006-06-16 | 하. 룬트벡 아크티에 셀스카브 | 우울증 치료를 위한 세로토닌 재흡수 억제제 및 글리신트랜스포터 타입 1 억제제의 조합 |
US7163954B2 (en) * | 2003-09-25 | 2007-01-16 | Wyeth | Substituted naphthyl benzothiophene acids |
EP1727785A1 (en) * | 2004-03-12 | 2006-12-06 | H.Lundbeck A/S | Phenyl indan derivatives |
WO2005100301A1 (en) * | 2004-03-31 | 2005-10-27 | Eli Lilly And Company | 2-aryloxyethyl glycine derivatives and their use as glycine transport inhibitors |
WO2006000222A2 (en) * | 2004-06-24 | 2006-01-05 | H. Lundbeck A/S | The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia |
RU2429222C2 (ru) * | 2006-07-18 | 2011-09-20 | Астеллас Фарма Инк. | Аминоиндановое производное или его соль |
EP2069286B1 (en) * | 2006-08-30 | 2012-09-19 | F. Hoffmann-La Roche AG | Inhibitors for glyt-1 |
US20100083581A1 (en) * | 2007-06-18 | 2010-04-08 | Mattice Douglas A | Environmental brush seal |
CA3037010A1 (en) | 2009-01-20 | 2010-07-29 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Cente | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical |
EP2380595A1 (en) | 2010-04-19 | 2011-10-26 | Nlife Therapeutics S.L. | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types |
US9700563B2 (en) * | 2012-09-06 | 2017-07-11 | MediSynergies, LLC | Kappa opioid receptor compounds |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1166711A (en) * | 1966-03-28 | 1969-10-08 | Kefalas As | Process for the Preparation of Phenyl-Indane and -Tetralin Derivatives |
US3549656A (en) * | 1967-12-28 | 1970-12-22 | Kefalas As | Antidepressant 1 - aminoalkyl - thiophthalanes and acid addition salts thereof |
GB1526331A (en) * | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
US5225323A (en) | 1988-11-21 | 1993-07-06 | Baylor College Of Medicine | Human high-affinity neurotransmitter uptake system |
EP0614487A4 (en) | 1991-11-12 | 1995-04-19 | Synaptic Pharma Corp | AND CODING A GLYCINE CONVEYOR AND ITS USES. |
US5824486A (en) | 1996-05-31 | 1998-10-20 | Allelix Neuroscience Inc. | Glycine transporter-transfected cells and uses thereof |
US6008015A (en) | 1997-04-11 | 1999-12-28 | Allelix Neuroscience Inc. | Glycine transporter |
AR021509A1 (es) * | 1998-12-08 | 2002-07-24 | Lundbeck & Co As H | Derivados de benzofurano, su preparacion y uso |
AR021155A1 (es) * | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | Tratamiento de desordenes neuroticos |
US6566550B2 (en) * | 2001-06-21 | 2003-05-20 | Pfizer Inc | Substituted aromatic ethers as inhibitors of glycine transport |
-
2001
- 2001-07-19 MX MXPA03000642A patent/MXPA03000642A/es not_active Application Discontinuation
- 2001-07-19 AT AT01960184T patent/ATE295844T1/de not_active IP Right Cessation
- 2001-07-19 KR KR10-2003-7000851A patent/KR20030015889A/ko not_active Application Discontinuation
- 2001-07-19 JP JP2002514122A patent/JP2004504393A/ja not_active Withdrawn
- 2001-07-19 DE DE60110914T patent/DE60110914T2/de not_active Expired - Fee Related
- 2001-07-19 CN CNB018158579A patent/CN100509791C/zh not_active Expired - Fee Related
- 2001-07-19 EA EA200300180A patent/EA005621B1/ru not_active IP Right Cessation
- 2001-07-19 PT PT01960184T patent/PT1301502E/pt unknown
- 2001-07-19 AU AU2001281740A patent/AU2001281740B2/en not_active Ceased
- 2001-07-19 PL PL01364439A patent/PL364439A1/xx not_active Application Discontinuation
- 2001-07-19 CZ CZ2003396A patent/CZ2003396A3/cs unknown
- 2001-07-19 NZ NZ523720A patent/NZ523720A/en unknown
- 2001-07-19 HU HU0302778A patent/HUP0302778A3/hu unknown
- 2001-07-19 UA UA2003010452A patent/UA75081C2/uk unknown
- 2001-07-19 AU AU8174001A patent/AU8174001A/xx active Pending
- 2001-07-19 CA CA002416447A patent/CA2416447A1/en not_active Abandoned
- 2001-07-19 BR BR0113011-0A patent/BR0113011A/pt not_active IP Right Cessation
- 2001-07-19 IL IL15398801A patent/IL153988A0/xx not_active IP Right Cessation
- 2001-07-19 EP EP01960184A patent/EP1301502B1/en not_active Expired - Lifetime
- 2001-07-19 SK SK202-2003A patent/SK2022003A3/sk unknown
- 2001-07-19 ES ES01960184T patent/ES2238466T3/es not_active Expired - Lifetime
- 2001-07-19 WO PCT/DK2001/000510 patent/WO2002008216A1/en not_active Application Discontinuation
- 2001-07-20 AR ARP010103460A patent/AR032358A1/es not_active Application Discontinuation
-
2003
- 2003-01-16 IL IL153988A patent/IL153988A/en unknown
- 2003-01-17 US US10/348,490 patent/US6921774B2/en not_active Expired - Fee Related
- 2003-01-17 NO NO20030243A patent/NO20030243L/no not_active Application Discontinuation
- 2003-01-20 IS IS6693A patent/IS6693A/is unknown
- 2003-01-20 ZA ZA200300514A patent/ZA200300514B/en unknown
- 2003-01-27 HR HR20030053A patent/HRP20030053A2/hr not_active Application Discontinuation
- 2003-02-05 BG BG107530A patent/BG107530A/bg unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0655055B1 (en) | Tachykinin antagonists | |
CN102066360B (zh) | 喹啉或异喹啉取代的p2x7拮抗剂 | |
JP2007527363A (ja) | バニロイドvr1受容体のモジュレーターであるキノリン誘導アミド | |
PL167994B1 (pl) | Sposób wytwarzania nowych aryloalkiloamin PL PL PL PL PL PL | |
GB2271774A (en) | Piperazine derivatives | |
HRP20030053A2 (en) | Novel compounds and their use as glycine transport inhibitors | |
SK13532000A3 (sk) | Bicyklo [2.2.1] heptány a príbuzné zlúčeniny, farmaceutické kompozície a spôsoby liečenia na ich báze | |
HRP980106A2 (en) | Atropisomers of 3-aryl-4 (3h)-quinazolinones | |
DE69608551T2 (de) | Bicyclische amin-derivate und ihre verwendung als antipsychotische wirkstoffe | |
KR100207876B1 (ko) | 치료학적으로 유용한 2-아미노테트랄린 유도체 | |
AU2005250197A1 (en) | Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics | |
AU2001281740A1 (en) | Novel compounds and their use as glycine transport inhibitors | |
JP4173912B2 (ja) | ニューロキニンアンタゴニストとしてのピペラジノ誘導体 | |
CA2179205A1 (en) | Benzisothiazolyl-substituted aminomethylchromans | |
SK160495A3 (en) | Isoquinoline derivatives as therapeutic agents | |
CA2112490A1 (en) | Diamine derivatives having selective affinity for sigma receptors | |
EP0585116B1 (en) | 1-Alkoxy-naphthalene-2-carboxamide derivatives with high affinity for the serotonin 5-HT1A receptor | |
US6063964A (en) | 5-hydroxymethyl-2-aminotetralins as cardiovascular agents | |
EP1171416B1 (en) | 3-bicycloaryl-2-aminomethyl bicycloalkanes as serotonine reuptake inhibitors | |
JP2740296B2 (ja) | アルコキシチオフェンカルボキシアミド誘導体、その製造方法及び該化合物を含有する医薬組成物 | |
KR101651994B1 (ko) | 아릴옥시 아제티딘 화합물, 및 이를 포함하는 약학 조성물 | |
WO2005021505A1 (en) | The claimed invention relates to novel 4-piperidinecarboxamide and the use thereof for the preparation of medicaments against 5-ht2a receptor-related disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20040701 Year of fee payment: 4 |
|
A1OB | Publication of a patent application | ||
OBST | Application withdrawn |